Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis. [PDF]
World J Gastroenterol, 2021 Acute pancreatitis (AP) is an inflammatory disease in which the regulatory pathway is complex and not well understood. Soluble suppression of tumorigenicity 2 (sST2) protein receptor functions as a decoy receptor for interleukin (IL)-33 to prevent IL-33/suppression of tumorigenicity 2L (ST2L)-pathway-mediated T helper (Th)2 immune responses.To ...
Zhang Y +7 more
europepmc +3 more sources
Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure. [PDF]
Anatol J Cardiol, 2018 [No abstract available]
Öncel CR.
europepmc +3 more sources
Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. [PDF]
Am J Respir Crit Care Med, 2021 Abstract Rationale Standard physiologic assessments of extubation readiness in patients with acute hypoxemic respiratory failure (AHRF) may not reflect lung injury resolution and could adversely affect clinical decision-making and patient outcomes.
Alladina J +11 more
europepmc +4 more sources
NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2. [PDF]
Med Sci MonitBACKGROUND Epicardial adipose tissue (EAT) and soluble suppression of tumorigenicity 2 (sST2) are valuable markers of myocardial fibrosis, but the relationship between EAT and sST2 remains controversial. This study aimed to evaluate the role of combined EAT measurements and levels of sST2 and the risk of major adverse cardiovascular events (MACEs) in ...
Yin J, Qiu B, Li T, Tao Y, Gu X.
europepmc +3 more sources
Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis. [PDF]
Dis Markers, 2021 Objective. Previous studies have controversial results about the prognostic role of soluble suppression of tumorigenicity 2 (sST2) in chronic kidney disease (CKD). Therefore, we conduct this meta-analysis to access the association between sST2 and all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events in patients with CKD. Methods.
Guo G, Huang A, Huang X, Xu T, Yao L.
europepmc +4 more sources
Soluble suppression of tumorigenicity 2 associated with left ventricular thrombosis in patients with ST-segment elevation myocardial infarction [PDF]
BMC Cardiovascular DisordersBackground Left ventricular thrombosis (LVT) after acute ST-segment elevation myocardial infarction (STEMI) is closely related to inflammation. Soluble Suppression of Tumorigenicity 2 (sST2) expressed as a novel inflammatory marker, has received much ...
Xinjia Du +6 more
doaj +2 more sources
Experimental Biology and Medicine, 2021 The soluble form of the suppression of tumorigenicity-2 (sST2) is a biomarker for risk classification and prognosis of heart failure, and its production and secretion in the alveolar epithelium are significantly correlated with the inflammation-inducing in pulmonary diseases.
Shixue Sun +2 more
exaly +3 more sources
Kidney & Blood Pressure ResearchIntroduction: Biomarkers are urgently required to identify peritoneal dialysis (PD) patients at risk of cardiovascular (CV) events. This study aimed to investigate the predictive value of soluble suppression of tumorigenicity-2 (sST2) for CV events in ...
Yunyun Zhang +7 more
doaj +2 more sources
Use of Soluble Suppression of Tumorigenicity 2 for Predicting the Need for Intubation and Mortality Outcomes in Patients with COVID-19 [PDF]
Mediterranean Journal of Infection, Microbes and AntimicrobialsIntroduction: Suppression of tumorigenicity 2 (ST2) plays a key role in the serious complications that may occur during Coronavirus disease-2019 (COVID-19), including systemic inflammatory condition, sepsis, Acute respiratory distress syndrome, and ...
Fatih ÇATAL +5 more
doaj +2 more sources
International Journal of Clinical PracticeBackground Pulmonary embolism (PE) is a serious cardiovascular condition associated with a wide range of clinical outcomes, from mild symptoms to severe hemodynamic compromise. Existing biomarkers like D‐dimer and proBNP have limitations in specificity and do not fully capture the inflammatory and hemodynamic ...
Ahmet Seyfeddin Gurbuz +2 more
doaj +2 more sources